Alvogen Acquires NAPRELAN® Tablets

PINE BROOK, N.J.--(BUSINESS WIRE)--Alvogen Pharma US, Inc. (“Alvogen”), the U.S. subsidiary of a multinational pharmaceutical company, today announced it has finalized a transaction with Shionogi Inc., acquiring the exclusive right to commercialize NAPRELAN® (naproxen sodium) controlled-release tablets, 375 mg, 500 mg, and 750 mg, in the United States. The product will be marketed by Almatica Pharma Inc., a subsidiary of Alvogen.

Help employers find you! Check out all the jobs and post your resume.